| Not Yet Recruiting | Study of CU06-1004 in Patients With Daibetic Macular Edema NCT07459829 | Curacle Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema NCT06881888 | University of Alabama at Birmingham | Phase 1 |
| Not Yet Recruiting | Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Pr NCT07481500 | Jakkrit Juhong | N/A |
| Not Yet Recruiting | Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal V NCT07501052 | Sam Chun Dang Pharm. Co. Ltd. | Phase 2 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participa NCT07425522 | Genentech, Inc. | Phase 1 |
| Not Yet Recruiting | Lactiplantibacillus Plantarum 299v Probiotic Supplementation in Patients With Diabetic Macular Edema NCT07383701 | Massachusetts Eye and Ear Infirmary | Phase 2 |
| Not Yet Recruiting | Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edem NCT07489131 | Alvotech Swiss AG | Phase 3 |
| Recruiting | COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME NCT07449936 | EyePoint Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME NCT07449923 | EyePoint Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | Kamuvudine-9 (K9) in Diabetic Macular Edema NCT07458061 | Dr. Bryan Strelow | Phase 1 / Phase 2 |
| Not Yet Recruiting | Wide Field OCTA in Ocular Diseases NCT07298174 | IRCCS San Raffaele | — |
| Not Yet Recruiting | OCT-Based Screening for Early Retinal Changes in Asymptomatic Diabetic Patients NCT07232225 | Assiut University | — |
| Not Yet Recruiting | Micropulse Laser Photocoagulation in Diabetic Macular Edema NCT07266597 | Sohag University | N/A |
| Not Yet Recruiting | A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients NCT07199777 | SciNeuro | Phase 2 |
| Recruiting | Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant NCT06984822 | Vastra Gotaland Region | N/A |
| Recruiting | Non-Center Involving Diabetic Macular Edema Progression in Early Postoperative Period After Phacoemulsificatio NCT07038967 | Ain Shams University | — |
| Recruiting | Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME) NCT06942520 | Sierra Eye Associates | Phase 2 |
| Terminated | Evaluation of K9 in Subjects With Diabetic Macular Edema (DME) NCT06781255 | Michelle Abou-Jaoude | Phase 1 |
| Recruiting | Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular Edema NCT06845163 | Alexandria University | Phase 2 |
| Recruiting | A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) NCT06680817 | Hoffmann-La Roche | — |
| Enrolling By Invitation | Implementation of the Intravitreal Injection Administered by Nurses NCT06511700 | Corporacion Parc Tauli | — |
| Recruiting | Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinop NCT06549023 | Vastra Gotaland Region | N/A |
| Completed | A Study Conducted to Evaluate the Conjunctiva and Tenon's Capsule Status of Healthy Subjects and in Participan NCT06723288 | Hoffmann-La Roche | — |
| Recruiting | A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy. NCT06701721 | Therini Bio Pty Ltd | Phase 1 |
| Completed | Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macula NCT05959304 | Novartis Pharmaceuticals | Phase 4 |
| Active Not Recruiting | A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants Wit NCT06548568 | AbbVie | — |
| Recruiting | Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT NCT06610747 | Zhongshan Ophthalmic Center, Sun Yat-sen University | N/A |
| Completed | Ocular Safety and Usability Study for FYB203 PFS NCT06708637 | Formycon AG | Phase 4 |
| Completed | A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of NCT06591598 | Bayer | Phase 4 |
| Recruiting | EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema NCT06536491 | Eclipse Life Sciences, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Ag NCT06491914 | Regeneron Pharmaceuticals | Phase 3 |
| Active Not Recruiting | Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent Diabetic Macular Ede NCT06498050 | Guangdong Provincial People's Hospital | Phase 4 |
| Not Yet Recruiting | Comparing Artificial Intelligence for Assisted Diagnosis of Diabetic Retinopathy NCT06423274 | Zhejiang University | — |
| Not Yet Recruiting | Exploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Dam NCT06272565 | Zhongshan Ophthalmic Center, Sun Yat-sen University | — |
| Recruiting | Evaluation of NeoRetina Artificial Intelligence Algorithm for the Screening of Diabetic Retinopathy at the CHU NCT04699864 | Centre hospitalier de l'Université de Montréal (CHUM) | N/A |
| Completed | A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants NCT06422507 | Bayer | Phase 3 |
| Recruiting | Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular NCT06439576 | Hoffmann-La Roche | — |
| Recruiting | A Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in NCT06237777 | Wang Min | Phase 1 |
| Active Not Recruiting | Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic R NCT06305143 | Shanghai Eye Disease Prevention and Treatment Center | Phase 4 |
| Recruiting | A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema NCT06305416 | Incepta Pharmaceuticals Ltd | Phase 3 |
| Active Not Recruiting | A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2 NCT06172257 | Oculis | Phase 3 |
| Unknown | Outcomes After Vitrectomy in Eyes With Tractional Diabetic Macular Edema NCT06316388 | Rehab Azzam | — |
| Recruiting | Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment NCT05728476 | Tianjin Medical University Eye Hospital | N/A |
| Unknown | Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients NCT06572553 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 / Phase 3 |
| Completed | Everads Injector in Suprachoroidal Administration of TA Suspension, for Treatment of Patients With DME NCT06314217 | Everads Therapy | N/A |
| Completed | Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) NCT06099184 | EyePoint Pharmaceuticals, Inc. | Phase 2 |
| Recruiting | Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME) NCT05802329 | Ocugen | Phase 1 |
| Completed | Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in S NCT05699759 | Michelle Abou-Jaoude | Phase 1 |
| Unknown | Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti NCT06205979 | Sohag University | EARLY_Phase 1 |
| Terminated | A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema NCT06181227 | Aviceda Therapeutics, Inc. | Phase 2 |
| Completed | Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic M NCT06878573 | Augenabteilung Allgemeines Krankenhaus Linz | — |
| Unknown | Assessment of Retinal Fundus Imaging Camera NCT06173232 | Digital Diagnostics, Inc. | — |
| Recruiting | Gene Therapy for DME NCT06492876 | Frontera Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | Effectiveness Of Suprachoroidal Injection In Diabetic Macular Edema NCT06449768 | Superior University | — |
| Active Not Recruiting | Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular NCT05978622 | AbbVie | — |
| Active Not Recruiting | A Study of ASKG712 in Patients With Diabetic Macular Edema NCT05940428 | AskGene Pharma, Inc. | Phase 1 |
| Unknown | OCT and OCT-Angiography Biomarkers of Treatment Response to Dexamethasone Implant in Macular Edema Due to Reti NCT06332690 | IRCCS Multimedica | — |
| Unknown | Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients NCT05990829 | Tianjin Medical University Eye Hospital | Phase 4 |
| Unknown | Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol NCT06262737 | University Hospital, Clermont-Ferrand | — |
| Completed | Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DM NCT06011798 | Unity Biotechnology, Inc. | Phase 2 |
| Active Not Recruiting | 4D-150 in Patients With Diabetic Macular Edema NCT05930561 | 4D Molecular Therapeutics | Phase 2 |
| Completed | Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macula NCT05697809 | Oxular Limited | Phase 2 |
| Completed | Describing Patient With DME, Their Patient Journey and Disease Progression NCT05966753 | Boehringer Ingelheim | — |
| Unknown | OphtAI Diagnostic Performance Validation for Automated Screening of Eye Diseases NCT05752045 | Evolucare Technologies | N/A |
| Completed | VISUPRIME® Eye Drops NCT05677685 | VISUfarma SpA | N/A |
| Recruiting | Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema NCT05885503 | RemeGen Co., Ltd. | Phase 3 |
| Unknown | Artificial Intelligence Diagnostic Aid NCT05675540 | Guy's and St Thomas' NHS Foundation Trust | — |
| Recruiting | Gene Therapy for Diabetic Macular Edema NCT05916391 | Frontera Therapeutics | Phase 1 |
| Active Not Recruiting | Evaluation of Tonabersat for DME NCT05727891 | Jaeb Center for Health Research | Phase 2 |
| Active Not Recruiting | Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi NCT05610319 | McMaster University | Phase 4 |
| Active Not Recruiting | Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-rela NCT05698329 | AiViva BioPharma, Inc. | Phase 1 |
| Completed | Detecting Eye Diseases Via Hybrid Deep Learning Algorithms From Fundus Images NCT06213896 | Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi | — |
| Completed | Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema: NCT05847088 | Dar El Oyoun Hospital | — |
| Completed | Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME) NCT05712720 | Rezolute | Phase 2 |
| Completed | Comparative Study Between IVI of Ranibizumab with and Without Prior ACP in Patients with DME Using OCT-A NCT05861466 | Ain Shams University | Phase 4 |
| Completed | The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME) NCT05573100 | Curacle Co., Ltd. | Phase 2 |
| Active Not Recruiting | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 NCT06847854 | Genentech, Inc. | Phase 1 |
| Active Not Recruiting | A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products NCT05476926 | Hoffmann-La Roche | — |
| Unknown | Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT NCT05745116 | Notal Vision Inc. | — |
| Completed | Validation Study of RETINA-AI Galaxy™ v2.0, an Automated Diabetic Retinopathy Screening Device NCT05368623 | RETINA-AI Health, Inc. | — |
| Unknown | Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to Aflibercept NCT05610488 | Vista Klinik | Phase 4 |
| Completed | A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate th NCT05569148 | Hoffmann-La Roche | Phase 3 |
| Unknown | Additional Effect of Subthreshold Micropulse Laser to Intravitreous Injection of Bevacizumab on Diabetic Macul NCT05582577 | Shahid Beheshti University of Medical Sciences | Phase 2 / Phase 3 |
| Withdrawn | Oxulumis®, Suprachoroidal Drug Administration of Triesence® in Diabetic Macular Edema NCT05172401 | Oxular Limited | N/A |
| Completed | Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection NCT05526729 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME NCT05387837 | Ashvattha Therapeutics, Inc. | Phase 2 |
| Completed | Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema NCT05512962 | Oxular Limited | Phase 2 |
| Completed | A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in P NCT05511038 | Bayer | Phase 4 |
| Active Not Recruiting | Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT) NCT05607810 | Adverum Biotechnologies, Inc. | — |
| Completed | A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema NCT05489718 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Unknown | Custom Needle Preparation for Suprachoroidal Steroid Injection (One Year Results) NCT05496530 | Benha University | N/A |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone o NCT06850922 | Genentech, Inc. | Phase 1 / Phase 2 |
| Unknown | Comparing Conventional Grid Laser Photocoagulation and Subthreshold Micropulse Laser in Diabetic Macular Edema NCT05416099 | Chinese University of Hong Kong | — |
| Completed | A Single Ascending Dose Cohort Study of AG-73305 in DME Patients NCT05301751 | Allgenesis Biotherapeutics Inc. | Phase 2 |
| Completed | Systemic and Local Inflammatory Biomarkers in the Treatment of Refractory Diabetic Macular Edema NCT06179030 | Saglik Bilimleri Universitesi | — |
| Completed | Bangladesh PRODUCTIVity in Eyecare Trial NCT05182580 | Orbis | N/A |
| Unknown | Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema NCT05324774 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 3 |
| Active Not Recruiting | A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabeti NCT05224102 | Genentech, Inc. | Phase 4 |
| Terminated | Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema NCT05333055 | Greater Houston Retina Research | — |
| Completed | Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model NCT04805541 | Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi | — |
| Completed | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administrati NCT05105607 | Ashvattha Therapeutics, Inc. | Phase 1 |
| Unknown | Anti-VEGF in Real-world NCT05222633 | Wenbin Wei | — |
| Completed | A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema NCT05151731 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema NCT05151744 | Hoffmann-La Roche | Phase 2 |
| Unknown | High Resolution Optical Coherence Tomography NCT05130385 | Insel Gruppe AG, University Hospital Bern | — |
| Terminated | Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema NCT04991350 | Cairo University | Phase 4 |
| Active Not Recruiting | VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases NCT05099094 | Shanghai BDgene Co., Ltd. | EARLY_Phase 1 |
| Suspended | Evaluation of IBI302 Injection in nAMD or DME NCT05961007 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 / Phase 2 |
| Terminated | EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN) NCT05127525 | iRenix Medical, Inc. | Phase 3 |
| Active Not Recruiting | A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual I NCT05112861 | Outlook Therapeutics, Inc. | Phase 3 |
| Recruiting | Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabet NCT04910503 | Centre Hospitalier Universitaire Dijon | Phase 4 |
| Active Not Recruiting | A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1 NCT05066997 | Oculis | Phase 2 / Phase 3 |
| Recruiting | Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin NCT06595355 | Isfahan University of Medical Sciences | Phase 2 / Phase 3 |
| Unknown | Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema NCT05083689 | Shahid Beheshti University of Medical Sciences | Phase 2 / Phase 3 |
| Completed | Observational Study of Vision Improvement in Patients With Retinal Disorders NCT04693702 | Optimal Acuity Corporation | — |
| Terminated | A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema. NCT05063734 | Oxurion | Phase 2 |
| Completed | First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers NCT04795037 | Curacle Co., Ltd. | Phase 1 |
| Unknown | Epidemiologic Assessment of Diabetic Retinopathy in Egypt Using Ultrawide Field Fundus Photographs NCT04935749 | Alexandria University | — |
| Completed | Ranibizumab 0.5 mg for Diabetic Macular Edema With Initial Intensive Treatment in the Real World Clinical Sett NCT05815212 | Novartis Pharmaceuticals | — |
| Completed | Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome NCT05080803 | European School of Advanced Studies in Ophthalmology | — |
| Unknown | Ozurdex in Suboptimal Diabetic Macular Edema Patients NCT04856397 | Uptown Eye Specialists | N/A |
| Completed | Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema NCT05217680 | Laboratorios Sophia S.A de C.V. | Phase 3 |
| Completed | Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy NCT04692688 | Ocuphire Pharma, Inc. | Phase 2 |
| Unknown | Study Comparing Two Populations of Patients Treated With Anti VEGF for Diabetic Macular Edema, One Being Follo NCT04776343 | Hospital St. Joseph, Marseille, France | N/A |
| Completed | Validation Study of RETINA-AI Galaxy™, an Automated Diabetic Retinopathy Screening Device NCT04774822 | RETINA-AI Health, Inc. | — |
| Completed | Evaluation of RC28-E Injection in Diabetic Macular Edema NCT04782115 | RemeGen Co., Ltd. | Phase 2 |
| Completed | The Effect of Ocular Rinse Volume on Surface Irritation After Intravitreal Injections NCT05615805 | University of Oklahoma | N/A |
| Completed | Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema NCT05324592 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 |
| Withdrawn | Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema NCT02229175 | University of California, San Francisco | Phase 2 / Phase 3 |
| Unknown | Prophylactic Effect of Conbercept Intravitreal Injection at the Conclusion of Cataract Surgery for Diabetic Ma NCT04668703 | Eye & ENT Hospital of Fudan University | N/A |
| Completed | Comparing the Compliance to Follow-up in Patients With Diabetic Macular Edema NCT05019807 | Lions Club International Foundation | N/A |
| Completed | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients NCT04635800 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injectio NCT04563299 | Retina Vitreous Associates of Florida | Phase 4 |
| Withdrawn | A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With NCT04588948 | Stanford University | Phase 2 |
| Active Not Recruiting | Pilot and Phase 2 Study of the Efficacy of a Treatment Protocol With Dexamethasone Implant Loading Dose in Pat NCT04116398 | Hospices Civils de Lyon | Phase 2 |
| Completed | Real-Life Study in Diabetic Macular Edema NCT05472376 | Kocaeli University | — |
| Completed | A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Di NCT04597918 | Hoffmann-La Roche | Phase 2 |
| Completed | Extension Study of MYL-1701P-3001 for Safety and Efficacy NCT04674800 | Mylan Pharmaceuticals Inc | Phase 3 |
| Completed | Time Efficiency Comparison of Two IntraVitreal Injection Techniques NCT04455399 | Peregrine Eye and Laser Institute | N/A |
| Completed | A Study to Evaluate the Safety and Tolerability of EXN407 NCT04565756 | Exonate Limited | Phase 1 / Phase 2 |
| Completed | Clinical Study of the Safety and Efficacy of BAT5906 Injection NCT04772105 | Bio-Thera Solutions | Phase 1 / Phase 2 |
| Completed | Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Ma NCT04537884 | Unity Biotechnology, Inc. | Phase 1 |
| Completed | A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders NCT04516278 | Outlook Therapeutics, Inc. | Phase 3 |
| Terminated | A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants Wi NCT04611152 | Kodiak Sciences Inc | Phase 3 |
| Terminated | A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants Wi NCT04603937 | Kodiak Sciences Inc | Phase 3 |
| Unknown | Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Dia NCT04464694 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Phase 4 |
| Active Not Recruiting | A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DM NCT04469595 | Alimera Sciences | Phase 4 |
| Completed | A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular E NCT04432831 | Hoffmann-La Roche | Phase 3 |
| Completed | A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema NCT04527107 | Oxurion | Phase 2 |
| Completed | Intravitreal Ranibizumab Versus Its Combination With Dexamethasone in The Treatment of Diabetic Macular Edema NCT05271539 | Cairo University | Phase 3 |
| Completed | Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease NCT04429503 | Regeneron Pharmaceuticals | Phase 2 / Phase 3 |
| Recruiting | MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema NCT04187443 | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. | Phase 1 |
| Completed | ADVM-022 Intravitreal Gene Therapy for DME NCT04418427 | Adverum Biotechnologies, Inc. | Phase 2 |
| Completed | Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) o NCT04395859 | Fondation Ophtalmologique Adolphe de Rothschild | — |
| Withdrawn | Cataract DME - Peri vs. Intraop NCT03920878 | Emory University | Phase 2 |
| Completed | Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema NCT04411693 | The Cleveland Clinic | Phase 4 |
| Unknown | Changes in Optical Coherence Tomography Leakage Mapping in Diabetic Macular Edema After Conbercept Treatment NCT04254536 | Renmin Hospital of Wuhan University | — |
| Completed | Influence of Cataract Surgery on Early DME The DICAT-II Study NCT04096131 | European School of Advanced Studies in Ophthalmology | — |
| Withdrawn | Intravitreal Dexamethasone Implant (Ozurdex) Versus Bevacizumab in Patients With Diabetic Macular Edema Underg NCT04067856 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | N/A |
| Unknown | Computer-based Tutorial and Automated Speech Recognition for Intravitreal Drug Injections NCT04142164 | Prim. Prof. Dr. Oliver Findl, MBA | N/A |
| Recruiting | A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in NCT04108156 | Hoffmann-La Roche | Phase 3 |
| Completed | A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occl NCT04085341 | Graybug Vision | Phase 2 |
| Completed | A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never NCT03953807 | Allergan | Phase 4 |
| Withdrawn | Combined Ranibizumab and Iluvien for Diabetic Macular Oedema NCT03784443 | Imperial College London | Phase 2 / Phase 3 |
| Completed | Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece NCT05683912 | University of Athens | — |
| Withdrawn | Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema NCT03629210 | Pradeepa Yoganathan | Phase 2 |
| Completed | IVI Aflibercept Before and After Phaco in DME. NCT05731089 | Al Hadi Hospital | N/A |
| Completed | To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edem NCT04058067 | Novartis Pharmaceuticals | Phase 3 |
| Unknown | Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery NCT04063358 | Second Military Medical University | Phase 3 |
| Unknown | Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME NCT04038125 | Retina Macula Specialists of Miami, LLC | Phase 4 |
| Completed | A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabe NCT06771271 | Hoffmann-La Roche | Phase 1 |
| Completed | Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular NCT03917472 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study) NCT04018482 | California Retina Consultants | Phase 4 |
| Completed | A Study Assessing AR-13503 Implant in Subjects With nAMD or DME NCT03835884 | Aerie Pharmaceuticals | Phase 1 |
| Completed | One Year Trial Evaluating Safety of Ozurdex With Eylea NCT03984110 | Texas Retina Associates | Phase 4 |
| Completed | Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema NCT03927690 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in DME Patients Treated Wit NCT03780361 | Hyewon Chung | Phase 4 |
| Unknown | Diabetic Macular Edema Asian Response (DEAR) Study: Biomarkers for Response to Aflibercept in Asian Patients W NCT03197480 | Singapore National Eye Centre | Phase 4 |
| Completed | Long Term Safety of Cooling Anesthesia for Intravitreal Injection NCT03956797 | Recens Medical, Inc. | N/A |
| Completed | A Pilot Study Evaluating Photobiomodulation Therapy for Diabetic Macular Edema NCT03866473 | Jaeb Center for Health Research | N/A |
| Unknown | The Study of Drug 601 in Patients With Diabetic Macular Edema (DME) NCT04151407 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1 |
| Unknown | Effect of Corona Virus on Intravitreal Injections NCT05494775 | Benha University | N/A |
| Completed | Barriers to Eye Screening for People With Diabetes in India NCT04544553 | Lions Club International Foundation | N/A |
| Completed | Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant NCT03889444 | Allergan | — |
| Terminated | Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokineti NCT03790852 | Kodiak Sciences Inc | Phase 1 |
| Unknown | Post Intravitreal Injection Topical NSAID vs. Patching NCT03918590 | The New York Eye & Ear Infirmary | Phase 4 |
| Completed | Cooling Anesthesia for Intravitreal Injection NCT03732287 | Recens Medical, Inc. | Phase 1 / Phase 2 |
| Completed | Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification NCT03832179 | Bay Area Retina Associates | Phase 4 |
| Active Not Recruiting | Predicting Diabetic Retinopathy From Risk Factor Data and Digital Retinal Images NCT03694145 | Charles Drew University of Medicine and Science | — |
| Completed | NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients NCT03969303 | Notal Vision Ltd. | — |
| Completed | A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Ede NCT03622593 | Hoffmann-La Roche | Phase 3 |
| Completed | Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME NCT03690947 | Beijing Hospital | Phase 4 |
| Completed | A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME) NCT03666923 | ThromboGenics | Phase 1 |
| Completed | A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Ede NCT03622580 | Hoffmann-La Roche | Phase 3 |
| Unknown | Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study NCT03762226 | University of Leipzig | — |
| Completed | Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macula NCT03610646 | Mylan Pharmaceuticals Inc | Phase 3 |
| Completed | A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to D NCT03481660 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabeti NCT03481634 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Advanced Glycation End Products Are Associated With Diabetic Macular Edema NCT04468152 | Hacettepe University | N/A |
| Unknown | Follow up of Diabetic Macular Edema Treated by Aflibercept (Eylea®) With OCT-Angiography NCT03783832 | Aquitania Opthalmologica | — |
| Withdrawn | Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab NCT03059277 | Southeast Clinical Research Associates, LLC | Phase 4 |
| Unknown | Navigation Laser Versus Traditional Laser Photocoagulation for Mild Diabetic Macular Edema NCT03641144 | Sun Yat-sen University | N/A |
| Unknown | Multimodal Image Study of Retinal Inflammation Markers After Corticoid and Antiangiogenic Treatment in Pacient NCT03583242 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | — |
| Completed | A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME) NCT03511898 | ThromboGenics | Phase 1 |
| Active Not Recruiting | Mean Visual Acuity Changes Following Five Injections of Aflibercept NCT02645266 | McMaster University | N/A |
| Completed | Micropulse for Suppression of Diabetic Macular Edema NCT03519581 | University of California, Davis | N/A |
| Unknown | Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection NCT03297684 | Advanced Eye Research Associates | — |
| Withdrawn | Evaluation of Bromocriptine, Metoprolol and Tamsulosin in Eyes With Non-Central DME NCT03384524 | Andrew Moshfeghi, MD, MBA | Phase 1 / Phase 2 |
| Completed | Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macu NCT03466099 | KalVista Pharmaceuticals, Ltd. | Phase 2 |
| Completed | Short-term Effect of Intravitreal Dexamethasone Implant in Refractory Diabetic Macular Edema NCT05736081 | Asociación para Evitar la Ceguera en México | Phase 4 |
| Completed | Curcumin and Intravitreal Dexamethasone in Diabetic Macular Edema NCT03598205 | Fondazione G.B. Bietti, IRCCS | N/A |
| Completed | Effect of Dexamethasone Implant on Optic Disc NCT03927118 | Bulent Ecevit University | — |
| Completed | A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema NCT03397264 | Opthea Limited | Phase 1 / Phase 2 |
| Terminated | PROMINENT-Eye Ancillary Study (Protocol AD) NCT03345901 | Jaeb Center for Health Research | Phase 3 |
| Unknown | Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Ede NCT03759860 | CynosureLutronic | Phase 4 |
| Unknown | The Results of Pars Plana Vitrectomy in Diabetic Macular Edema NCT03384901 | Hillel Yaffe Medical Center | — |
| Unknown | Diabetic Macular Edema - Obstructive Sleep Apnea Relationship Study NCT03597815 | Uptown Eye Specialists | — |
| Unknown | Obstructive Sleep Apnea and Diabetic Macular Edema Inflammatory Mediators NCT04648618 | Uptown Eye Specialists | — |
| Completed | DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME NCT03321513 | Jaeb Center for Health Research | Phase 3 |
| Completed | Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopat NCT03490318 | Belfast Health and Social Care Trust | — |
| Completed | Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Usi NCT03246152 | Cairo University | Phase 4 |
| Completed | Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME) NCT03003416 | Allergan | — |
| Completed | Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept NCT03453281 | Indonesia University | Phase 4 |
| Completed | Efficacy and Safety of Dexamethasone Nanoparticles Eye Drops in Diabetic Macular Edema NCT05343156 | Oculis | Phase 2 |
| Terminated | Comparison of VA Guided Versus OCT Guided TER Using Aflibercept for Diabetic Macular Edema (AVOCT Study) NCT03394573 | Insel Gruppe AG, University Hospital Bern | — |
| Unknown | Screening For Diabetic Macular Edema Among Diabetic Patients Using Optical Coherence Tomography NCT03240458 | Assiut University | — |
| Completed | Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Mac NCT04387604 | Centro Hospitalar do Porto | — |
| Completed | Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular NCT03126786 | Clearside Biomedical, Inc. | Phase 2 |
| Completed | Ranibizumab vs Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema NCT04089605 | Far Eastern Memorial Hospital | Phase 4 |
| Recruiting | Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edem NCT03161652 | Carmen Clapp | Phase 2 |
| Completed | Aflibercept With and Without Micropulse Laser in Diabetic Macular Edema NCT03866746 | Al Hadi Hospital | Phase 4 |
| Unknown | Diabetic Retinopathy Assessed by Ultra-wide NCT03157206 | Association Pour La Recherche En Vision Du Service D'Ophtalmologie De L'Hôpital | — |
| Completed | Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis NCT03097068 | Vitreo-Retinal Associates, Michigan | Phase 4 |
| Completed | Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool NCT03112005 | Eyenuk, Inc. | — |
| Completed | Treatment of Diabetic Macular Edema With Aflibercept and Micropulse Laser NCT03143192 | Keyvan Koushan | Phase 2 / Phase 3 |
| Withdrawn | Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study NCT02902744 | Johns Hopkins University | Phase 4 |
| Unknown | Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab NCT03056092 | Unity Health Toronto | Phase 4 |
| Unknown | Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept NCT03056079 | Unity Health Toronto | Phase 4 |
| Completed | Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO NCT04619303 | Lions Eye Institute, Perth, Western Australia | Phase 4 |
| Completed | 30g vs 33g Needle for Intravitreal Injections NCT03038048 | Wills Eye | N/A |
| Unknown | Rapid Structural and Functional Improvements in Following 0.19 mg Fluocinolone Acetonide (FAc) Implant in Diab NCT03590587 | Benha University | — |
| Completed | Sub-macular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema NCT03975088 | University of Alexandria | N/A |
| Completed | Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME) NCT04087746 | Minia University | Phase 4 |
| Completed | Ranibizumab Versus Dexamethasone Implant in Diabetic Macular Edema NCT03385382 | G. d'Annunzio University | — |
| Completed | Outcomes of Subthreshold Laser Versus Intravitreal Injection of Ranibizumab in Diabetic Macular Edema NCT04332133 | Minia University | N/A |
| Completed | iOCT for Patients With Diabetic Macular Edema NCT03328715 | Vienna Institute for Research in Ocular Surgery | N/A |
| Completed | Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema NCT02949024 | Clearside Biomedical, Inc. | Phase 1 / Phase 2 |
| Completed | Intravitreal Aflibercept InjectiOn in Vitrectomized Eyes for Treatment of Diabetic Macular Edema NCT02874859 | Lille Catholic University | — |
| Unknown | Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema NCT02924987 | Maisonneuve-Rosemont Hospital | Phase 4 |
| Completed | Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections NCT02951351 | Mayo Clinic | N/A |
| Withdrawn | Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study NCT02511067 | University of Nebraska | Phase 2 |
| Completed | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA6 NCT02867735 | Novartis Pharmaceuticals | Phase 1 |
| Withdrawn | Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular E NCT02842541 | Eleven Biotherapeutics | Phase 1 |
| Completed | Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME) NCT02914613 | OcuTerra Therapeutics, Inc. | Phase 1 / Phase 2 |
| Unknown | Identifying Patients With Unrecognized Treatable Diabetic Macular Edema NCT01934920 | Elman Retina Group | — |
| Completed | Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema NCT02985619 | University of Sao Paulo | Phase 2 / Phase 3 |
| Unknown | OCT-angiography in Diabetic Patients NCT02870803 | Retina Clinic, Sao Paulo, Brazil | — |
| Terminated | Adaptive Optics for Ophthalmic Technologies NCT02826655 | Duke University | N/A |
| Completed | Effect of Dexamethasone on Reduction of Macular Thickness in Diabetic Patients, a Randomized Clinical Trial NCT03608839 | Universidade Federal de Pernambuco | Phase 2 |
| Completed | A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema NCT02699450 | Hoffmann-La Roche | Phase 2 |
| Completed | One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab NCT03974425 | University of Alexandria | N/A |
| Completed | Aflibercept Plus Micropulse Laser Versus Aflibercept Monotherapy for Diabetic Macular Edema NCT04014556 | University of Alexandria | N/A |
| Unknown | PROTECT2: Diabetes Care - Eye Exam NCT03094819 | Retinal Care Inc. | N/A |
| Completed | Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for NCT02712008 | Regeneron Pharmaceuticals | Phase 2 |
| Unknown | Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabet NCT02651168 | Unity Health Toronto | Phase 4 |
| Completed | Anti-VEGF Treatment for Prevention of PDR/DME NCT02634333 | Jaeb Center for Health Research | Phase 3 |
| Completed | 3 Month Outcome of Ziv-aflibercept for DME NCT02772497 | Marashi Eye Clinic | Phase 2 / Phase 3 |
| Withdrawn | A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema NCT02281292 | Alcon Research | Phase 1 |
| Recruiting | Aflibercept in Recurrent or Persistent CNV NCT02669953 | Medical University of Vienna | — |
| Completed | Pain and Visual Outcome in Intravitreal Bevacizumab Injection NCT02790775 | Shahid Beheshti University of Medical Sciences | Phase 2 |
| Terminated | Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema NCT02684084 | North Toronto Eye Care Laser and Eye Specialists | Phase 4 |
| Completed | Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Mac NCT02329132 | Kagawa University | — |
| Completed | Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide NCT02221453 | Unity Health Toronto | Phase 2 |
| Completed | Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO NCT02503540 | Justis Ehlers | Phase 4 |
| Completed | Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema NCT02441907 | Unity Health Toronto | Phase 4 |
| Completed | The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabet NCT02448446 | South Coast Retina Center; Carson, McBeath, Boswell, Inc. | Phase 1 / Phase 2 |
| Completed | Study of DS-7080a for the Treatment of Macular Degeneration NCT02530918 | Daiichi Sankyo | Phase 1 |
| Terminated | SD-OCT Angiography NCT02510885 | Duke University | N/A |
| Completed | Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema NCT02471651 | California Retina Consultants | Phase 4 |
| Completed | Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan i NCT02663141 | Tehran University of Medical Sciences | Phase 2 |
| Completed | IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab NCT03340610 | Southeast Retina Center, Georgia | Phase 4 |
| Completed | Imaging Parameters and DME Treatment Response NCT02637245 | Duke University | — |
| Completed | Variable Interval Versus Set Interval Aflibercept for DME NCT02392364 | California Retina Consultants | Phase 4 |
| Completed | Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab NCT02107131 | California Retina Consultants | Phase 4 |
| Unknown | The Effects of Intravitreal Ozurdex Implant in DME NCT03475407 | Nune Eye Hospital, Seoul, Korea | Phase 4 |
| Completed | Alzer® and Diamel® to Prevent Severe Diabetes Macular Edema NCT03533478 | Catalysis SL | Phase 2 |
| Completed | Intra-individual Variability and Circadian Rhythm of VEGF Levels and Interaction With Biomarkers NCT02325271 | GWT-TUD GmbH | — |
| Completed | Prevalence of DIAbetic RETinopathy and Impact of Genetic Factors in the Development of Diabetic Retinopathy of NCT02232503 | Novartis Slovakia, s.r.o. | — |
| Completed | Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME. NCT02571972 | Wills Eye | Phase 2 |
| Completed | A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME NCT02302079 | Astellas Pharma Europe B.V. | Phase 2 |
| Unknown | Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With Ranibi NCT03973138 | Sun Yat-sen University | Phase 1 / Phase 2 |
| Unknown | Conjunctival Flora Patterns After Serial Intravitreal Injections in Diabetic Patients NCT02337972 | Sheba Medical Center | N/A |
| Completed | Short-pulse Subthreshold vs Infrared Micropulse for Diabetic Macular Edema NCT04505306 | Moorfields Eye Hospital Centre Abu Dhabi | N/A |
| Completed | Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME NCT02363621 | Arshad Khanani | Phase 2 |
| Completed | 577nm Micropulse Laser Versus 532nm Subthreshold Laser Photocoagulation for Diabetic Macular Edema NCT02406157 | Sun Yat-sen University | N/A |
| Unknown | Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema. NCT03458923 | Cairo University | Phase 4 |
| Completed | The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema NCT02796183 | Neon Hospital | N/A |
| Completed | Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME NCT02262260 | Novartis Pharmaceuticals | Phase 3 |
| Unknown | Spectral-domain Optical Coherence Tomography of the Eye NCT02614625 | Augenabteilung Allgemeines Krankenhaus Linz | — |
| Completed | Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DM NCT02299336 | Greater Houston Retina Research | Phase 4 |